REG - Angle PLC - Notice of Preliminary Results and Webcast

AngleAnnouncement

20/04/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220420:nRST6695Ia&default-theme=true

RNS Number : 6695I  Angle PLC  20 April 2022

 For immediate release   20 April 2022

 

ANGLE plc ("the Company")

 

Notice of Preliminary Results and Webcast

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, will
be releasing its preliminary results for the year ended 31 December 2021 on
Thursday 28 April 2022.

 

A meeting for analysts will be held at 10:00 am BST on Thursday 28 April 2022
at the offices of Berenberg, 60 Threadneedle Street, London, EC2R 8HP.

 

A live webcast of the analyst meeting can be accessed via ANGLE's Investor
Centre page, https://angleplc.com/investor-relations/regulatory-news/
(https://angleplc.com/investor-relations/regulatory-news/) , with Q&A
participation reserved for analysts only. Please register in advance and log
on to the webcast approximately 5 minutes before 10:00 am on the day of the
results. A recording of the webcast will be made available on ANGLE's website
following the results meeting.

 

For further information:

 

 ANGLE plc                                   +44 (0) 1483 343434
 Andrew Newland, Chief Executive

 Ian Griffiths, Finance Director

 Andrew Holder, Head of Investor Relations

 Berenberg (NOMAD and Joint Broker)

 Toby Flaux, Ciaran Walsh, Milo Bonser       +44 (0) 20 3207 7800

 Jefferies (Joint Broker)                    +44 (0) 20 7029 8000

 Max Jones, Thomas Bective

 FTI Consulting

 Simon Conway, Ciara Martin                  +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                    +1 (212) 850 5624

 

For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
(https://angleplc.com/investor-relations/glossary/)

 

Notes for editors

 

About ANGLE plc www.angleplc.com (http://www.angleplc.com)

ANGLE is a world leading liquid biopsy company with sample-to-answer
solutions. ANGLE's proven patent protected platforms include a circulating
tumor cell (CTC) harvesting technology and a downstream analysis system for
cost effective, highly multiplexed analysis of nucleic acids and proteins.

 

ANGLE's cell separation technology is called the Parsortix(®) system, and it
enables a liquid biopsy (a simple blood test) to be used to provide the cells
of interest to the user in a format suitable for multiple types of downstream
analyses.  The system is based on a microfluidic device that captures cells
based on a combination of their size and compressibility.  The system is
epitope independent and can capture all types of CTCs as well as CTC clusters
in a viable form (alive).  CTCs enable the complete picture of a cancer to be
seen; as being an intact cell they allow DNA, RNA and protein analysis and may
provide comparable analysis to a tissue biopsy. Because CTC analysis is a
non-invasive process, unlike tissue biopsy, it can be repeated as often as
needed. This is important because cancer develops and changes over time and
there is a clear medical need for up-to-date information on the status of a
patient's tumor. In addition, the live CTCs harvested by the Parsortix system
can be cultured, which offers the potential for testing tumor response to
drugs outside the patient.

 

The Parsortix technology is the subject of 26 granted patents in Europe, the
United States, China, Australia, Canada, India, Japan and Mexico with three
extensive families of patents are being progressed worldwide.

 

The Parsortix system has a CE Mark in Europe for the indicated use and, in the
United States, a De Novo Submission has been made to FDA for the Parsortix(®)
PC1 system seeking FDA clearance with Class II Classification for use with
metastatic breast cancer patients. FDA clearance is seen as the global
standard. ANGLE is seeking to be the first ever FDA cleared system for
harvesting CTCs for subsequent analysis.

 

ANGLE has also completed two separate 200 subject clinical studies under a
program designed to develop an ovarian cancer pelvic mass triage test, with
the results showing best in class accuracy (AUC-ROC) of 95.1%. The pelvic mass
triage assay has undergone further refinement and optimisation and a 200
patient clinical verification study has now completed enrolment.

 

ANGLE's technology for the multiplex evaluation of proteins and nucleic acids
of all types is called the HyCEAD(TM) platform and is based on a patented flow
through array technology. It provides for low cost, highly multiplexed, rapid
and sensitive capture of targets from a wide variety of sample types. A
proprietary chemistry approach (the HyCEAD method) allows for the capture and
amplification of over 100 biomarkers simultaneously in a single reaction. The
HyCEAD system is extremely sensitive and is ideal for measuring gene
expression and other markers directly from Parsortix harvests and was used in
the ovarian cancer pelvic mass triage test to achieve best in class accuracy
(AUC-ROC) of 95.1%.

 

ANGLE's proprietary technologies can be combined to provide automated,
sample-to-answer results in both centralised laboratory and point-of-use
cartridge formats.

 

ANGLE has established formal collaborations with world-class cancer centres
and major corporates such as Abbott, Philips and QIAGEN, and works closely
with leading CTC translational research customers. These Key Opinion Leaders
(KOLs) are working to identify applications with medical utility (clear
benefit to patients), and to secure clinical data that demonstrates that
utility in patient studies. The body of evidence as to the benefits of the
Parsortix system is growing rapidly from our own clinical studies in
metastatic breast cancer and ovarian cancer and also from KOLs with 59
peer-reviewed publications and numerous publicly available posters, available
on our website.

 

ANGLE has established clinical services laboratories in the UK and USA to
accelerate commercialisation of the Parsortix system and act as demonstrators
to support product development. The laboratories offer services to
pharmaceutical and biotech customers for use of Parsortix in cancer drug
trials and, once the laboratories are accredited and tests validated, will
provide Laboratory Developed Tests (LDTs) for patient management.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORILMMTMTTBTPT